Market revenue in 2023 | USD 50.3 million |
Market revenue in 2030 | USD 79.2 million |
Growth rate | 6.7% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 56.66% in 2023. Horizon Databook has segmented the UAE inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
The UAE pharmaceuticals market is witnessing rapid growth. Although UAE currently imports majority of its pharmaceuticals, the scenario is expected to be changing, as some international pharmaceutical giants have partnered with UAE companies to manufacture products in the country.
The growth of UAE inflammatory bowel disease treatment market can be attributed to government initiatives, such as launch of awareness programs and presence of medical centers, that provide various medical services for IBD.
For instance, healthcare facilities such as the Digestive Health & Endoscopy Consultants Dubai, UAE and Gastroenterology Clinic of Kings College Hospital provide medical treatments using biological therapies, including adalimumab, ustekinumab, tofacitinib, infliximab, and vedolizumab.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into UAE inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account